Small peptides specifically bind to colorectal cancers
Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32 P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.
1. A method of delivering a radioactive isotope to a colon adenocarcinoma cell, comprising:
administering to a colon adenocarcinoma cell a radioactive isotope-labeled peptide, wherein the peptide is a substrate for protein kinase A (PKA) comprising
the sequence of SEQ ID NO: 5.
2. The method of claim 1 wherein the radioactive isotope is 32 P or 33 P.
3. The method of claim 1 wherein the radioactive isotope is 125 I or 131 I.
4. The method of claim 1 wherein the adenocarcinoma cell is in a patient with a colon tumor.
5. The method of claim 1 further comprising the step of:
determining location of the radioactive isotope in the patient by an imaging technique.
6. The method of claim 1 further comprising the step of:
monitoring size of the tumor.
7. The method of claim 1 wherein the adenocarcinoma cell is in a xenograft in an animal.
8. The method of claim 1 wherein the adenocarcinoma cell is in culture.